ClinicalTrials.gg
RecruitingNCT05196074AiCLOSEUpdated May 10, 2024

Airway Closure During Extracorporeal Membrane Oxygenation: The AiCLOSE Study

An observational study in Acute Hypoxemic Respiratory Failure, sponsored by Lorenzo delSorbo. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2024-05-10.

Sponsored by Lorenzo delSorbo · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
299
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 94 studies in Respiratory Insufficiency with a site in Canada — 24 open to participants now, 29 under way, 1 of them phase 3. Respiratory Insufficiency · Canada.

Planned enrollment
6th of 28
299 · median 118
Started
2022
with 5 others
Observational
28 of 94
9 open now
Primary completion
2025-04
later than 4 of 28 live
Registered
72nd of 94
by date
Lead sponsor
2 of 94
Lorenzo delSorbo

Among the 94 studies in Respiratory Insufficiency with a site in Canada, this one is the 6th largest by planned enrollment of the 28 observational ones that give a count, is one of 6 that started in 2022, is one of 28 observational ones, reaches primary completion later than 4 of the 28 other live ones, and was the 72nd registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

24 of the 94 studies in Respiratory Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Respiratory Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

About 65,000 Canadians develop acute respiratory failure requiring breathing machines (ventilators) to give oxygen to their lungs. Unfortunately, up to 50% of these individuals will not survive their illness.

Mechanical ventilation through breathing machines, though potentially lifesaving, may further injure the lungs and the respiratory muscles. In the patients with the most severe and life threatening forms of respiratory failure a breathing machine alone may not be able to provide enough oxygen to the lungs and vital organs. In these critical situations, patients may require an artificial lung machine, which is referred to as extracorporeal membrane oxygenation (ECMO) to temporarily replace the function of the patient's own lung and supply critical oxygen to the body, while protecting the damaged lungs. How to use the breathing machine safely while a patient is on ECMO is still unknown. Using conventional breathing machine settings while on ECMO can lead to large portions of the lungs or airway to remain collapsed, which can contribute to further lung damage.

The investigators have recently discovered a way of detecting if patients on a breathing machine suffer from collapsed airways. Knowing if the most severe patients on ECMO have airway collapse is a pivotal question that the investigators plan to answer in our study. The investigators will use our technique to determine how many patients on ECMO have airway closure and determine if this contributes to a longer time on ECMO and a longer time on a breathing machine, and if this impacts a patient's survival in the intensive care unit.

03

Conditions studied

  • Acute Hypoxemic Respiratory Failure
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Acute hypoxemic respiratory failure patients on VV-ECMO.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Acute hypoxemic respiratory failure
  • VV-ECMO
  • Less than 24 hours from ECMO cannulation

Exclusion criteria

Exclusion Criteria:

  • Air leak
  • VV-ECMO as bridge to lung transplantation
  • Status asthmaticus
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
299 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute hypoxemic respiratory failure patients on VV-ECMO

    Other: Acute hypoxemic respiratory failure patients on VV-ECMO

Interventions

  • OtherAcute hypoxemic respiratory failure patients on VV-ECMO

    To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.

06

What researchers measure

Primary outcomes

  1. Prevalence of complete airway closure

    Prevalence of complete airway closure during day 1 of VV-ECMO support.

    Time frame: Day 1 of VV-ECMO cannulation

Secondary outcomes

  1. Correlation of airway closure with patient outcomes

    Evaluation of the correlation between the presence of complete airway closure and the level of airway opening pressure and both clinical and physiological outcomes listed below: a. Clinical outcomes i. duration of ECMO support at 90 days ii. duration of mechanical ventilation at 90 days iii. ICU mortality iv. mortality at 90 days v. prevalence of barotrauma vi. daily ECMO support I. sweep gas II. Flow vii. Daily fluid balance b. Physiological outcomes i. time to recovery I. In spontaneous modes of ventilation compliance will be measured by dividing tidal volume by driving pressure ii. time to protective spontaneous breathing (defined as: a. ventilator not continuously triggered by the patient I. Pocc is measured by performing an end-expiratory occlusion maneuver, freezing the ventilator waveform and measuring the drop in airway pressure. iii. lung recruitability iv. right ventricular dysfunction

    Time frame: Up to 90 days from VV-ECMO cannulation

  2. Correlation of the degree of mismatch between clinical PEEP and AOP with patient outcomes

    Evaluation of the correlation between the degree of mismatch between clinical PEEP and AOP and patient outcomes listed below: a. Clinical outcomes i. duration of ECMO support at 90 days ii. duration of mechanical ventilation at 90 days iii. ICU mortality iv. mortality at 90 days v. prevalence of barotrauma vi. daily ECMO support I. sweep gas II. Flow vii. Daily fluid balance b. Physiological outcomes i. time to recovery I. In spontaneous modes of ventilation compliance will be measured by dividing tidal volume by driving pressure ii. time to protective spontaneous breathing (defined as: a. ventilator not continuously triggered by the patient I. Pocc is measured by performing an end-expiratory occlusion maneuver, freezing the ventilator waveform and measuring the drop in airway pressure. iii. lung recruitability iv. right ventricular dysfunction

    Time frame: Up to 90 days from VV-ECMO cannulation

  3. Assessment of the distribution of airway closure within the lung and between the two lungs

    Assessment of the distribution of airway closure within the lung and between the two lungs by EIT.

    Time frame: Up to 90 days from VV-ECMO cannulation

  4. Assessment of predictors of airway closure

    Assessment of body mass index and the degree of obesity as predictors of airway closure.

    Time frame: Up to 90 days from VV-ECMO cannulation

07

Study locations

1 of 1 sites recruiting
  • Toronto General Hospital
    Toronto, Ontario M5G 2N2, Canada
    Recruiting
    • Hesham Abdelhady, B Pharm · ContactHesham.Abdelhady@uhn.ca · 416-340-4800
    • Lorenzo Del Sorbo, MD · Principal investigator
    • Niall Ferguson, MD · Sub investigator
    • Eddy Fan, MD · Sub investigator
    • Ewan Goligher, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Apr 2025, 36 months after the start.

Of 232 non-industry observational studies under Respiratory Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's planned 36 months is above that.

Counting every sponsor, half of 248 studies reached it within 22 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Jan 19, 2022
StartActual
Apr 4, 2022
Primary completionEst.
Apr 2025
CompletionEst.
Apr 2026
Last update
May 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05196074
Lead sponsor
Lorenzo delSorbo
Responsible party
Lorenzo delSorbo (MD, Critical Care Medicine Department, Toronto General Hospital, University Health Network, Toronto) — Sponsor-investigator
First posted
Jan 19, 2022
Start date
Apr 4, 2022
Primary completion
Apr 2025 (estimated)
Completion
Apr 2026 (estimated)
Last update
May 10, 2024

Study contacts

Hesham Abdelhady, B Pharm
Contact
Hesham.Abdelhady@uhn.ca
416-340-4800 ext. 6056
Lorenzo Del Sorbo, MD
principal investigator · University Health Network, Toronto
Laurent Brochard, MD
principal investigator · Unity Health Toronto
Michael Sklar, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion